In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stelo Launch And Dispelling GLP-1s: Dexcom’s Sayer Speaks

Executive Summary

Dexcom’s CEO, Kevin Sayer, ahead of this year’s Advanced Technologies & Treatments for Diabetes conference, shared an update on the company’s recent news, future strategy and where he feels the market is headed.

You may also be interested in...



Are GLP-1 Major Threat To The Insulin Delivery Tech Market?

A small scale study has indicated that GLP-1 agonists could restore normal HbA1c levels in type I diabetics. This therapy could be a huge step forward for the treatment of this chronic disease if this benefit is shown in larger studies.

Moving Pharma Execs Out Of The Shadows Is Key To Building Public Trust

2024 Rising Leader, Jack O’Meara, says the industry must ‘promote personalities’ when building new biotech businesses to gain the trust of investors and the public. 

Deals Shaping The Industry, February 2024

An interactive look at pharma, medtech, and diagnostics deals made during February 2023. Data courtesy of Biomedtracker.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV148733

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel